Comparing Evaxion A/S (NASDAQ:EVAX) & Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals (NASDAQ:RXRX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Recursion Pharmaceuticals and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-697.15%	-47.85%	-36.26%
Evaxion A/S	N/A	-61.43%	-34.23%

Insider and Institutional Ownership

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Recursion Pharmaceuticals and Evaxion A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1	2	2	0	2.20
Evaxion A/S	1	0	4	0	2.60

Recursion Pharmaceuticals currently has a consensus target price of $8.18, indicating a potential upside of 132.06%. Evaxion A/S has a consensus target price of $11.25, indicating a potential upside of 294.74%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Recursion Pharmaceuticals.

Risk & Volatility

Recursion Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Earnings and Valuation

This table compares Recursion Pharmaceuticals and Evaxion A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68 million	25.27	-$644.76 million	($0.90)	-3.92
Evaxion A/S	$7.53 million	3.41	-$7.71 million	($1.21)	-2.36

Evaxion A/S has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Evaxion A/S beats Recursion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

About Evaxion A/S

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to develop novel immunotherapies and vaccines. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease-specific targets and support the development of treatments tailored to individual patients or pathogens. The company’s research and development activities focus primarily on personalized cancer vaccines and vaccines for infectious diseases. Evaxion’s pipeline has included programs intended to stimulate the immune system to recognize and attack cancer cells, as well as vaccine candidates targeting bacterial and viral infections.